Keywords: Abbott,, PanGenetics, Licensing, Chronic pain, NGF

Abbott to acquire PanGenetics’ novel investigational biologic for chronic pain for up to $190 million

Article | 13 November 2009

US health care major Abbott says it has signed a definitive agreement to acquire the global rights to Dutch firm PanGenetics BV's early-stage PG110 fully-humanized antibody to Nerve Growth Factor (NGF), aiming to expand the company's pain care portfolio and leveraging its expertise in biologics.

The agreement includes an upfront $170 million plus additional milestone payments, for a total of up to $190 million. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in